Patients hospitalized for acute heart failure differ with respect of many clinical characteristics which may influence their prognosis and response to treatment.
Researchers have assessed possible differences in the effects of Serelaxin ( Reasanz ) on dyspnoea relief, 60 Day outcomes and 180 Day mortality across patient subgroups in the RELAX-AHF trial.
Subgroups were based on pre-specified covariates ( age, sex, race, geographic region, estimated glomerular filtration rate, time from presentation to randomization, baseline systolic blood pressure, history of diabetes, atrial fibrillation, ischaemic heart disease, cardiac devices, i.v. nitrates at randomization ).
Other covariates which may modify the efficacy of acute heart failure treatment were also analysed.
Subgroup analyses did not show any difference in the effects of Serelaxin versus placebo on dyspnoea relief or on the incidence of cardiovascular death or rehospitalizations for heart failure or renal failure at 60 days.
Nominally significant interactions between some patient subgroups and the effects of Serelaxin on 180 days cardiovascular and all-cause mortality were noted but should be interpreted cautiously due to the number of comparisons and the low incidence of deaths in the subgroups at lower risk.
In conclusion, the effects of Serelaxin versus placebo has appeared to be similar across subgroups of patients in RELAX-AHF. ( Xagena )
Metra M et al, Eur Heart J 2013; 34: 3128-3136